Literature DB >> 17279428

Designing randomized clinical trials in pediatric neurosurgery.

Peter Kan1, John R W Kestle.   

Abstract

OBJECTIVES: Randomized clinical trials provide the best evidence for making treatment decisions and their use in pediatric neurosurgery is increasing. In this paper, we review the basic principles of clinical trial design and discuss the unique challenges in trial design in pediatric neurosurgery.
MATERIALS AND METHODS: To illustrate the basic principles of trial design and highlight the special considerations in pediatric neurosurgery, examples from the Shunt Design Trial and Endoscopic Shunt Insertion Trial were used.
CONCLUSIONS: Each trial should answer one primary study question. Sample size estimates based on error rates and clinically important difference must be calculated. Allocation concealment, randomization, and blinding are critical to prevent selection and ascertainment bias. Standardization of the intervention is important to the result's validity, and study centers/surgeons should be selected on the basis of the trial objective. The effects of dropouts, crossovers, and missing data should be handled with an intention-to-treat analysis. Sample selection, informed consent, and valid outcome measures are specific challenges in the pediatric population.

Mesh:

Year:  2007        PMID: 17279428     DOI: 10.1007/s00381-006-0293-2

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  14 in total

1.  Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease.

Authors:  T B Freeman; D E Vawter; P E Leaverton; J H Godbold; R A Hauser; C G Goetz; C W Olanow
Journal:  N Engl J Med       Date:  1999-09-23       Impact factor: 91.245

2.  Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!).

Authors:  D L Sackett
Journal:  CMAJ       Date:  2001-10-30       Impact factor: 8.262

3.  Is placebo surgery unethical?

Authors:  Sam Horng; Franklin G Miller
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

4.  The natural history of hydrocephalus. Detailed analysis of 182 unoperated cases.

Authors:  K M LAURENCE; S COATES
Journal:  Arch Dis Child       Date:  1962-08       Impact factor: 3.791

Review 5.  Clinical economics and noncoronary vascular disease.

Authors:  J S Schwartz
Journal:  J Vasc Interv Radiol       Date:  1995 Nov-Dec       Impact factor: 3.464

Review 6.  Basic statistics for clinicians: 1. Hypothesis testing.

Authors:  G Guyatt; R Jaeschke; N Heddle; D Cook; H Shannon; S Walter
Journal:  CMAJ       Date:  1995-01-01       Impact factor: 8.262

Review 7.  Informed consent in surgical trials.

Authors:  E Etchells
Journal:  World J Surg       Date:  1999-12       Impact factor: 3.352

8.  Assessing differences in clinical trials comparing surgical vs nonsurgical therapy: using common (statistical) sense.

Authors:  G Howard; L E Chambless; R A Kronmal
Journal:  JAMA       Date:  1997-11-05       Impact factor: 56.272

9.  Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial.

Authors:  John R W Kestle; James M Drake; D Douglas Cochrane; Ruth Milner; Marion L Walker; Rick Abbott; Frederick A Boop
Journal:  J Neurosurg       Date:  2003-02       Impact factor: 5.115

10.  Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus.

Authors:  J M Drake; J R Kestle; R Milner; G Cinalli; F Boop; J Piatt; S Haines; S J Schiff; D D Cochrane; P Steinbok; N MacNeil
Journal:  Neurosurgery       Date:  1998-08       Impact factor: 4.654

View more
  1 in total

1.  Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.

Authors:  April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa
Journal:  Trials       Date:  2015-09-18       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.